UGT2B17 and B-cell chronic lymphocytic leukemia: For example, an initial study of 320 patients with CLL prior to therapy initiation showed that high UGT2B17 mRNA levels in leukaemic B cells are strongly associated with shorter treatment-free and overall survival.50 A second report validated UGT2B17 as an informative prognostic marker in a Scandinavian cohort of 253 CLL patients and also among CLL patients with a mutated immunoglobulin heavy-chain variable region gene, a group for which few prognostic indicators exist.57 These studies imply a relevant role of the UGT2B17 pathway in progressive CLL and provide novel prognostic information.